REG-BARCLAYS PLC Form 8.3 - WILLIS TOWERS WATSON PLC - AMENDMENT
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201218:nBw6WNNN1a&default-theme=true
Form 8.3 - WILLIS TOWERS WATSON PLC - AMENDMENT
Ap19
FORM 8.3 - Amendment to Sales
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR
MORE
1. KEY INFORMATION
Name of person dealing (Note 1) Barclays PLC.
Company dealt in WILLIS TOWERS WATSON PLC
Class of relevant security to which the ORD
dealings being disclosed relate (Note 2)
Date of dealing 15 December 2020
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security dealt in (Note 3)
Class of relevant security: ORD
Long Short
Number (%) Number (%)
(1) Relevant securities
3,063,010 2.38% 688,681 0.53%
(2) Derivatives (other than options):
597,705 0.46% 739,005 0.57%
(3) Options and agreements to
purchase/sell: 0 0.00% 0 0.00%
TOTAL:
3,660,715 2.84% 1,427,686 1.11%
(b) Interests and short positions in relevant securities of the company, other
than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
Purchase 1 209.0700 USD
Purchase 1 210.9900 USD
Purchase 2 209.4100 USD
Purchase 2 208.9550 USD
Purchase 3 210.6883 USD
Purchase 6 209.4633 USD
Purchase 6 207.9700 USD
Purchase 8 209.7787 USD
Purchase 11 209.6518 USD
Purchase 17 210.3670 USD
Purchase 22 208.5900 USD
Purchase 26 208.7991 USD
Purchase 34 209.5905 USD
Purchase 35 209.7302 USD
Purchase 47 209.0212 USD
Purchase 50 208.4804 USD
Purchase 51 210.0464 USD
Purchase 61 210.0398 USD
Purchase 62 208.4996 USD
Purchase 62 209.0048 USD
Purchase 100 207.8500 USD
Purchase 100 205.9800 USD
Purchase 100 205.9750 USD
Purchase 130 207.9557 USD
Purchase 160 206.1612 USD
Purchase 390 210.0112 USD
Purchase 391 206.2492 USD
Purchase 564 205.5971 USD
Purchase 583 206.5156 USD
Purchase 646 206.0739 USD
Purchase 905 206.0579 USD
Purchase 1,028 206.0686 USD
Purchase 1,599 210.2986 USD
Purchase 2,278 209.1042 USD
Purchase 2,410 206.7553 USD
Purchase 2,610 210.0100 USD
Purchase 3,521 207.0939 USD
Purchase 3,702 209.7766 USD
Purchase 6,489 210.0022 USD
Purchase 7,717 209.4994 USD
Purchase 12,591 209.7934 USD
Purchase 12,905 209.9904 USD
Sale 1 210.6400 USD
Sale 1 210.6300 USD
Sale 1 210.5500 USD
Sale 5 210.0060 USD
Sale 11 209.6518 USD
Sale 91 206.5100 USD
Sale 100 205.5800 USD
Sale 132 210.5012 USD
Sale 200 205.5857 USD
Sale 264 205.6121 USD
Sale 302 209.6935 USD
Sale 400 210.0001 USD
Sale 603 210.3212 USD
Sale 719 209.7810 USD
Sale 766 208.4364 USD
Sale 1,004 210.2810 USD
Sale 2,721 210.0100 USD
Sale 6,947 209.9503 USD
Sale 7,717 209.4994 USD
Sale 11,318 206.8584 USD
Sale 12,905 209.9904 USD
Sale 14,585 209.8751 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
e.g. call option
(ii) Exercising
Product name, Number of securities Exercise price per unit (Note 5)
e.g. call option
(d) Other dealings (including transactions in respect of new securities) (Note
4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing
and any other person relating to the voting rights of any relevant securities under any option
referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this
should be stated.
NONE
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 18 Dec 2020
Contact name: Large Holdings Regulatory Operations
Telephone number: 020 3134 7213
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection
View source version on businesswire.com:
https://www.businesswire.com/news/home/20201218005180/en/
(https://www.businesswire.com/news/home/20201218005180/en/)
BARCLAYS PLC
Copyright Business Wire 2020Recent news on Barclays
See all newsREG - Barclays PLC Life Science REIT - Form 8.3 LIFE SCIENCE REIT PLC
AnnouncementREG - Barclays PLC SolGold PLC - Form 8.3 SOLGOLD PLC
AnnouncementREG - Barclays PLC Senior PLC - Form 8.3 SENIOR PLC
AnnouncementREG - Barclays PLC Kitwave Group PLC - Form 8.3 KITWAVE GROUP PLC
AnnouncementREG - Barclays PLC Spire Healthcare Grp - Form 8.3 SPIRE HEALTHCARE GROUP PLC
Announcement